Thanks for posting that Led. In addition to this symposium, Resverlogix will have 3 other presentations at ESC 2017.

August 27 Poster (speaker Jan JOHANSSON) "Lowering the neutrophil to lymphocyte ratio by the BET inhibitor, apabetalone: potential implications for cardiovascular events in high risk patients"

August 27 moderated poster (speaker Daisuke SHISHIKURA from Adelaide, Australia) "The effect of apabetalone on attenuated coronary atherosclerotic plaque: insights from the ASSURE trial."

August 29 poster (speaker Ewelina KULIKOWSKI) "Apabetalone (RVX-208) impacts key biomarkers and pathways associated with cardiovascular disease in patients with severe renal impairment"